阿拉斯加州百日咳疫情期间6月龄至6岁儿童DTaP疫苗效果评估
完成3剂基础免疫的儿童调整疫苗效果为96.2%,部分接种者为85.3%;未接种儿童实验室确诊百日咳的比值约为接种≥3剂者的26倍。
要点
- 完成3剂DTaP基础免疫的6月龄至6岁儿童调整疫苗效果达96.2%。
- 未接种DTaP儿童实验室确诊百日咳的比值约为接种≥3剂者的26倍。
- 结果强化了遵循百日咳疫苗接种建议以保护儿童和减少暴发的的重要性。
核心结论
- 在2024年阿拉斯加百日咳暴发期间,6月龄至6岁儿童完成3剂DTaP基础免疫对百日咳具有高保护效果。
- 未接种或仅部分接种DTaP的儿童百日咳风险显著高于完成基础免疫者。
主要发现
- 完成3剂DTaP基础免疫的儿童调整疫苗效果为96.2%。
- 部分接种DTaP的儿童调整疫苗效果为85.3%。
- 与接种≥3剂DTaP者相比,未接种儿童实验室确诊百日咳的调整比值比(OR)为26.1。
- 与接种≥3剂DTaP者相比,接种1-2剂DTaP者实验室确诊百日咳的调整OR为3.8。
临床怎么用
- 应遵循百日咳疫苗接种建议,确保儿童完成DTaP基础免疫系列以预防百日咳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Widespread use of pertussis vaccines in children has resulted in a >90% reduction in the number of annual pertussis cases in the United States. After a period of low U.S. pertussis incidence during and shortly after the COVID-19 pandemic, incidence increased in 2024. Data on the real-world effectiveness of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) against pertussis during this disease resurgence are limited. In response to documentation of a record high pertussis incidence in Alaska during May-November 2024, DTaP vaccine effectiveness (VE) against pertussis in Alaska children aged 6 months-6 years was evaluated. Adjusted VE was 96.2% among children who had completed the 3-dose primary DTaP series and 85.3% among those who were partially vaccinated. Compared with children who had received ≥3 DTaP doses, the odds of laboratory-confirmed pertussis were approximately 26 times as high in unvaccinated children (adjusted odds ratio [OR] = 26.1), and approximately 4 times as high in those who had received 1-2 DTaP doses (adjusted OR = 3.8). These findings reinforce the importance of following pertussis vaccination recommendations to protect for children from the disease and reduce the occurrence of pertussis outbreaks.
引用
- Newell K, Ohlsen E, Moore K, et al. Effectiveness of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine in Children Aged 6 Months-6 Years During a Statewide Pertussis Outbreak - Alaska, May-November 2024. MMWR Morb Mortal Wkly Rep. 2026. PMID: 42879706. doi:10.15585/mmwr.mm7540a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。